As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.
9 Analysts have issued a Repare Therapeutics Inc forecast:
9 Analysts have issued a Repare Therapeutics Inc forecast:
Jun '25 |
+/-
%
|
||
Revenue | 0.25 0.25 |
100%
100%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -110 -110 |
18%
18%
|
EBIT (Operating Income) EBIT | -114 -114 |
19%
19%
|
Net Profit | -110 -110 |
59%
59%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using synthetic lethality approach in Canada. It provides SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The company's lead product candidate is RP-3500 a potent and selective oral small molecule inhibitor of ATR for the treatment of tumors with mutations in ataxia-telangiectasia mutated kinase. It also develops CCNE1-SL, a proprietary drug discovery program for tumors with amplification of CCNE1; and polymerase theta inhibitor. The company was founded in 2016 and is headquartered in St. Laurent, Canada.
Head office | Canada |
CEO | Steve Forte |
Employees | 129 |
Founded | 2016 |
Website | www.reparerx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.